China Biologic Products, Inc. (NASDAQ:CBPO) hit a new 52-week low during trading on Thursday . The company traded as low as $88.01 and last traded at $86.71, with a volume of 688,720 shares. The stock had previously closed at $97.15.

A number of brokerages have recently commented on CBPO. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. China Biologic Products presently has a consensus rating of “Hold” and a consensus price target of $137.50.

The company has a market capitalization of $2.31 billion, a PE ratio of 22.10 and a beta of 1.75. The stock’s 50 day moving average price is $93.75 and its 200-day moving average price is $103.38.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm had revenue of $89.28 million for the quarter, compared to the consensus estimate of $97.33 million. During the same quarter in the prior year, the company posted $1.26 earnings per share. The firm’s revenue was down 2.3% on a year-over-year basis. Analysts anticipate that China Biologic Products, Inc. will post $4.95 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. grew its holdings in China Biologic Products by 37.1% during the second quarter. Wasatch Advisors Inc. now owns 191,596 shares of the biopharmaceutical company’s stock valued at $21,670,000 after purchasing an additional 51,846 shares during the last quarter. Hillhouse Capital Management Ltd. grew its holdings in China Biologic Products by 186.8% during the second quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock valued at $85,235,000 after purchasing an additional 490,874 shares during the last quarter. Macquarie Group Ltd. grew its holdings in China Biologic Products by 115.3% during the second quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock valued at $66,456,000 after purchasing an additional 314,700 shares during the last quarter. AHL Partners LLP acquired a new position in China Biologic Products during the second quarter valued at approximately $842,000. Finally, Goldman Sachs Group Inc. grew its holdings in China Biologic Products by 4.9% during the second quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock valued at $6,945,000 after purchasing an additional 2,845 shares during the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: “China Biologic Products, Inc. (CBPO) Reaches New 1-Year Low at $88.01” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/12/china-biologic-products-inc-cbpo-reaches-new-1-year-low-at-88-01.html.

About China Biologic Products

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.